 |
 |
hi Ray, The phase II trial involved sterotactic brain surgery, and used a "gene transfer product, a disabled virus with a gene called GAD, will be infused into the STN bilaterally using stereotactic surgical techniques. The overall goal of this approach is to normalize the activity of the STN and reduce the motor symptoms of PD." (http://clinicaltrials.gov/ct2/show/NCT00643890?term=gad&cond=parkinsons&rank=1 It also stated that fior the phase II trial, previous brain surgery was an exclusion, we will have to wait awhile to learn what the trial III protocol will be like. linda www.pdpipeline.org ---------- Original Message ---------- From: Rayilyn Brown <[log in to unmask]> To: [log in to unmask] Subject: Re: Neurologix announces phase 2 trial is a success Date: Thu, 24 Jun 2010 10:42:52 -0700 do you know what brain surgery is involved? I've had DBS does that disqualify me? -------------------------------------------------- From: "[log in to unmask]" <[log in to unmask]> Sent: Wednesday, June 23, 2010 8:14 PM To: <[log in to unmask]> Subject: Fw: Neurologix announces phase 2 trial is a success > Neurologix Announces Successful Phase 2 Trial of Gene Therapy for > Parkinson's Disease > > FORT LEE, N.J., June 22 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC > Bulletin Board:NRGX.ob - News), today announced positive results in a > Phase 2 trial of its investigational gene therapy for advanced Parkinson's > disease (PD), NLX-P101. Study participants who received NLX-P101 > experienced statistically significant and clinically meaningful > improvements in off-medication motor scores compared to control subjects > who received sham surgery. In the trial, this benefit was seen at one > month and continued virtually unchanged throughout the six month blinded > study period. The results also demonstrated a positive safety profile for > NLX-P101, with no serious adverse events related to the gene therapy or > surgical procedure reported. Patients enrolled in the trial had moderate > to advanced PD and were not adequately responsive to current therapies. > http://finance.yahoo.com/news/Neurologix-Announces-prnews-2701823243.html?x=0&.v=1 > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: > mailto:[log in to unmask] > In the body of the message put: signoff parkinsn ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn